BACKGROUND AND PURPOSE: Vascular endothelial growth factor inhibitors (VEGFIs) and receptor (VEGFR) blockers are a standard-of-care treatment for cancer, but they can induce pulmonary vascular disease (PVD) in some patients. Moreover, patients with certain polymorphisms in glucose-6-phosphate dehydrogenase (G6PD) are more susceptible to PVD. Therefore, we sought to determine the potential mechanisms that contribute to VEGFI-induced PVD in wild-type rats and in CRISPR-engineered rats with a non-deficient (N126D) and a deficient (S188F) G6PD polymorphism. EXPERIMENTAL APPROACH: , s.c.) a VEGFR-2 blocker and determined right ventricular pressure. We performed histology and multiple omics approaches to determine the mechanism of SU-induced PVD. KEY RESULTS: SU increased right ventricular pressure in rats with a non-deficient (N126D) but not a deficient (S188F) glucose-6-phosphate dehydrogenase G6PD polymorphism. In addition, we uncovered that differences in the organization of the 3D genome and expression of genes encoding DNA and histone demethylases, cancer-related proteins, plasminogen activator inhibitor-1 (PAI-1) and inflammatory cytokines/chemokines (interleukin-1β IL-1β and CCL5) between the G6PD variants contributed to the disparate effects of VEGFR-2 blockade. For instance, VEGFR-2 blocker-induced expression of PAI-1 correlated positively with PVD in patients and evoked migration of pulmonary arterial smooth muscle cells. CONCLUSION AND IMPLICATIONS: This suggests that our findings reflect a heretofore unknown connection between G6PD polymorphisms and the 3D genomic organization that controls VEGFR blocker-induced expression of DNA/histone demethylases. Potential effects include up-regulation of genes encoding proteins, which evoke cell migration and inflammation within the lungs and contribute to the pathogenesis of PVD.
Signoretti et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: